close
close

Bleakley Financial Group LLC Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Bleakley Financial Group LLC Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)


Bleakley Financial Group LLC acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) during the 1st quarter, according to the fund’s most recent filing with the Securities and Exchange Commission. The fund acquired 6,147 shares of the company’s stock, valued at approximately $223,000.

Several other hedge funds and other institutional investors have also modified their holdings in the company. China Universal Asset Management Co. Ltd. increased its position in Tarsus Pharmaceuticals by 362.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,832 shares of the company’s stock worth $78,000 after acquiring an additional 3,004 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Tarsus Pharmaceuticals by 22.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company’s stock worth $92,000 after acquiring an additional 824 shares in the last quarter. Nations Financial Group Inc. IA ADV acquired a new position in Tarsus Pharmaceuticals in the 1st quarter worth approximately $218,000. Simplicity Wealth LLC acquired a new position in Tarsus Pharmaceuticals in the 1st quarter worth approximately $223,000. Finally, Sargent Investment Group LLC acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $225,000. 90.01% of the shares are held by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. HC Wainwright increased their price target on Tarsus Pharmaceuticals from $57.00 to $61.00 and gave the company a “buy” rating in a research report on Monday, May 13th. Barclays increased their price target on Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, May 10th. Finally, Oppenheimer increased their price target on Tarsus Pharmaceuticals from $59.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, May 9th. One research analyst has rated the stock with a hold rating and six have given it a buy rating. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $51.29.

Get our latest stock report on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Price Development

Shares of TARS opened at $27.04 on Friday. The stock has a 50-day moving average price of $31.24 and a 200-day moving average price of $31.16. The company has a debt-to-equity ratio of 0.11, a quick ratio of 7.92 and a current ratio of 8.01. Tarsus Pharmaceuticals, Inc. has a 12-month low of $12.57 and a 12-month high of $42.50.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last released its quarterly earnings results on Wednesday, May 8. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.14. The company had revenue of $27.61 million during the quarter, compared to the consensus estimate of $17.94 million. As a group, sell-side analysts expect Tarsus Pharmaceuticals, Inc. to post -3.73 EPS for the current fiscal year.

About Tarsus Pharmaceuticals

(Free Report)

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, is focused on the development and commercialization of novel therapeutic candidates for eye care in the United States. The Company’s lead product candidate is XDEMVY, a novel therapeutic treatment for the treatment of blepharitis caused by Demodex mites and for the treatment of meibomian gland disease.

Recommended Articles

Institutional Ownership by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)



Get daily news and reviews for Tarsus Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Tarsus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.